
X
EMA starts review of Xtandi in hormone-sensitive prostate cancer
https://pharmaphorum.com/news/ema-starts-review-of-xtandi-in-hormone-sensitive-prostate-cancer/
South Korean firm looking to develop novel drugs
Drug could be filed after “outlier” analysis.